Intended for healthcare professionals

Letters Industry payments and low value cancer drugs

Authors’ reply to Laurent

BMJ 2023; 383 doi: (Published 04 December 2023) Cite this as: BMJ 2023;383:p2832
  1. Aaron P Mitchell, assistant attending1,
  2. Aaron N Winn, associate professor2
  1. 1Memorial Sloan Kettering Cancer Center, New York, NY, USA
  2. 2University of Illinois Chicago, Chicago, IL, USA
  1. mitchea2{at}

Laurent raises several thoughtful questions regarding our sub-cohort focused on the use of denosumab in castration sensitive prostate cancer.12

In summary, the question is whether our methods distinguished use of denosumab for prevention of osteoporotic fractures (which would be appropriate) versus prevention of skeletal related events (SREs) (which would not be recommended). …

View Full Text

Log in

Log in through your institution


* For online subscription